Menu
Back to User profile » Dr Hiromichi Yamane
Papers published by Dr Hiromichi Yamane:
IgA Vasculitis in a Lung Cancer Patient During Chemoradiotherapy
Taoka M, Ochi N, Mimura A, Ichiyama N, Nagasaki Y, Nakagawa N, Nakanishi H, Yamane H, Oshiro Y, Monobe Y, Takigawa N
Therapeutics and Clinical Risk Management 2021, 17:571-575
Published Date: 3 June 2021
Descending necrotizing mediastinitis in a healthy young adult
Ochi N, Wakabayashi T, Urakami A, Yamatsuji T, Ikemoto N, Nagasaki Y, Nakagawa N, Honda Y, Nakanishi H, Yamane H, Monobe Y, Akisada T, Katayama H, Naomoto Y, Takigawa N
Therapeutics and Clinical Risk Management 2018, 14:2013-2017
Published Date: 17 October 2018
Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: a comparison of serum Krebs von Lungen-6 and thymus and activation-regulated chemokine/CC chemokine ligand 17
Yamane H, Ochi N, Nagasaki Y, Yamagishi T, Honda Y, Nakagawa N, Takeyama M, Nakanishi H, Takigawa N
Therapeutics and Clinical Risk Management 2018, 14:1457-1465
Published Date: 21 August 2018
Acute necrotizing encephalopathy in an adult with influenza A infection
Ochi N, Takahashi K, Yamane H, Takigawa N
Therapeutics and Clinical Risk Management 2018, 14:753-756
Published Date: 20 April 2018
Patients with osteosarcoma and soft tissue sarcoma might become "cancer refugees" in some Japanese regional cities
Yamane H, Kunisada T, Ozaki T, Ochi N, Honda Y, Nagasaki Y, Nakagawa N, Yamagishi T, Nakanishi H, Takigawa N
Cancer Management and Research 2018, 10:353-359
Published Date: 19 February 2018
Herpetic esophagitis following bendamustine-containing regimen
Yamane H, Monobe Y, Tanikawa T, Ochi N, Honda Y, Kawamoto H, Takigawa N
Therapeutics and Clinical Risk Management 2016, 12:883-886
Published Date: 2 June 2016
Circulating thymus and activation-regulated chemokine/CC chemokine ligand 17 is a strong candidate diagnostic marker for interstitial lung disease in patients with malignant tumors: a result from a pilot study
Yamane H, Ochi N, Yamagishi T, Honda Y, Takeyama M, Takigawa N
Therapeutics and Clinical Risk Management 2015, 11:949-959
Published Date: 17 June 2015
Cisplatin-induced hyponatremia in malignancy: comparison between brand-name and generic formulation
Ochi N, Yamane H, Hotta K, Fujii H, Isozaki H, Honda Y, Yamagishi T, Kubo T, Tanimoto M, Kiura K, Takigawa N
Drug Design, Development and Therapy 2014, 8:2401-2408
Published Date: 3 December 2014
Obstructive jaundice caused by intraductal metastasis of lung adenocarcinoma
Ochi N, Goto D, Yamane H, Yamagishi T, Honda Y, Monobe Y, Kawamoto H, Takigawa N
OncoTargets and Therapy 2014, 7:1847-1850
Published Date: 7 October 2014
Docetaxel for non small cell lung cancer harboring the activated EGFR mutation with T790M at initial presentation
Yamane H, Ochi N, Yasugi M, Tabayashi T, Yamagishi T, Monobe Y, Hisamoto A, Kiura K, Takigawa N
OncoTargets and Therapy 2013, 6:155-160
Published Date: 6 March 2013